Potent antibacterial compounds

Pyrrolomycin-based compounds for the treatment of bacterial infections

  • Nanomolar MICs against gram positive bacteria (MRSA and Anthrax)
  • Low micromolar MICs against gram negative bacteria
  • More potent than vancomycin and ciprofloxacin

Technology Manager: Matt Boehm, Ph.D.
mboehm@unmc.edu or 402-559-2166


New compounds fight antibiotic resistant bacteria

UNMC researcher Rongshi Li, Ph.D., (left) meets with Niall O’Donnell, of the venture capital firm RiverVest, during UNeMed’s 2016 Industry Partnering Summit held at UNMC’s Michael F. Sorrell Center on May 10, 2016.

Researchers at the University of Nebraska Medical Center have developed a set of promising antibacterial compounds that can effectively wipeout bacteria such as MRSA and anthrax.
Antibiotic resistance is a major health concern. Development of new and improved drugs is necessary to fight off antibiotic resistant strains of bacteria.
The new antibacterial compounds have shown some impressive results. UNMC researchers developed lead compounds that were effective in small concentrations, exhibiting remarkable nanomolar potency against MRSA and anthrax. One compound was tested against two powerful antibiotics currently available: ciprofloxacin and vancomycin. The new compound’s potency was similar to ciprofloxacin against anthrax and was 27 times more potent than vancomycin against MRSA.
Some of the new compounds also showed broad spectrum activity, but with low micromolar potency against key Gram-negative bacteria such as A. baumannii, Enterobacter, and K. pneumonia. New compounds are also being designed to improve activity against Gram-negative bacteria.
Researchers are evaluating some of the lead compounds in vivo against MRSA and anthrax.
To discuss licensing opportunities please contact Matt Boehm, Ph.D., at mboehm@unmc.edu or 402-559-2166.

Additional Information

Novel fluorinated pyrrolomycins as potent anti-staphylococcal biofilm agents: Design, synthesis, pharmacokinetics and antibacterial activities
Patent: PCT filed